首页> 外文期刊>Pharmacoepidemiology and drug safety >Hepatitis B vaccine and risk of autoimmune thyroid disease: a Vaccine Safety Datalink study.
【24h】

Hepatitis B vaccine and risk of autoimmune thyroid disease: a Vaccine Safety Datalink study.

机译:乙肝疫苗和自身免疫性甲状腺疾病的风险:疫苗安全性数据链研究。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

PURPOSE: Hepatitis B vaccine has been postulated as a possible cause of autoimmune disorders, including autoimmune thyroid diseases (ATD). Cases of Graves' disease and Hashimoto's thyroiditis, following hepatitis B vaccine have been reported to the Vaccine Adverse Events Reporting System (VAERS). To test the hypothesis that hepatitis B vaccine increases the risk of ATD, we conducted a case-control study, within the Vaccine Safety Datalink project. METHODS: We identified potential cases of Graves' disease and Hashimoto's thyroiditis, among persons aged 18-69 years from administrative data recorded by three health maintenance organizations (HMOs) and verified cases by medical record review. Controls were frequency-matched to cases by birth year, sex, and study site. Vaccine information was collected from administrative records, chart review, and telephone interviews with study subjects. We enrolled 355 Graves' disease cases, 418 Hashimoto's thyroiditis cases, and 1102 controls. We assessed the association between ever-receipt of hepatitis B vaccine, as well as receipt of hepatitis B vaccine less than 1 year, 1-5 years and at least 5 years prior to the index date, and the risk of ATD. RESULTS: Ever-receipt of hepatitis B vaccine was not associated with risk of Graves' disease (odds ratio (OR), 0.90; 95% confidence interval (CI), 0.62-1.32) or Hashimoto's thyroiditis (OR, 1.23; 95%CI, 0.87-1.73). There was also no association between the time interval since receipt of hepatitis B vaccination and either outcome. CONCLUSIONS: We did not observe an increased risk of Graves' disease or Hashimoto's thyroiditis, following receipt of hepatitis B vaccine.
机译:目的:乙型肝炎疫苗被假定为自身免疫性疾病的可能原因,包括自身免疫性甲状腺疾病(ATD)。乙肝疫苗接种后,格雷夫斯氏病和桥本甲状腺炎的病例已报告给疫苗不良事件报告系统(VAERS)。为了检验乙型肝炎疫苗会增加ATD风险的假说,我们在疫苗安全数据链项目中进行了病例对照研究。方法:我们从三个健康维持组织(HMO)记录的行政数据中,确定了18-69岁年龄段人群中潜在的Graves病和Hashimoto甲状腺炎病例,并通过病历审查对病例进行了验证。根据出生年份,性别和研究地点,对对照组进行频率匹配。从行政记录,图表审查以及对研究对象的电话采访中收集了疫苗信息。我们纳入了355例Graves病病例,418例桥本甲状腺炎病例和1102例对照。我们评估了曾经收到的乙型肝炎疫苗以及在索引日期前不到1年,1-5年和至少5年的乙型肝炎疫苗接种与ATD风险之间的关系。结果:乙型肝炎疫苗的再次接收与格雷夫斯病(几率(OR),0.90; 95%置信区间(CI),0.62-1.32)或桥本甲状腺炎(OR,1.23; 95%CI)的风险无关。 ,0.87-1.73)。接受乙肝疫苗接种后的时间间隔与任何一种结局之间也没有关联。结论:在接种乙型肝炎疫苗后,我们没有发现格雷夫斯病或桥本甲状腺炎的风险增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号